Strong upregulation of AIM2 and IFI16 inflammasomes in the mucosa of patients with active inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 21, Issue 11, 2015, Pages 2673-2682

  Vanhove, Wiebe ^a   Peeters, Paul M ^b,c   Staelens, Dominiek ^a   Schraenen, Anica ^d   Van Der Goten, Jan ^a   Cleynen, Isabelle ^a   De Schepper, Sebastiaan ^a   Van Lommel, Leentje ^d   Reynaert, Niki L ^b   Schuit, Frans ^d   Van Assche, Gert ^a   Ferrante, Marc ^a   De Hertogh, Gert ^e   Wouters, Emiel F M ^b   Rutgeerts, Paul ^a   Vermeire, Séverine ^a   Nys, Kris ^a   Arijs, Ingrid ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c IUF LEIBNIZ RESEARCH INSTITUTE FOR ENVIRONMENTAL MEDICINE   (Germany)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

Author keywords

inflammasome; inflammatory bowel disease; mucosal gene expression

Indexed keywords

AIM2 PROTEIN; CELL PROTEIN; DIFFERENTIATION ANTIGEN; HIGH MOBILITY GROUP B1 PROTEIN; IFI16 INFLAMMASOME; INFLAMMASOME; INFLIXIMAB; INTERLEUKIN 1BETA CONVERTING ENZYME; MYELOID CELL NUCLEAR DIFFERENTIATION ANTIGEN; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; UNCLASSIFIED DRUG; AIM2 PROTEIN, HUMAN; DNA BINDING PROTEIN; HMGB1 PROTEIN, HUMAN; IFI16 PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHOPROTEIN;

ARTICLE; COHORT ANALYSIS; COLON BIOPSY; COLON MUCOSA; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; INTESTINE EPITHELIUM CELL; LYMPHOCYTE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ADULT; AGED; BIOPSY; CASE CONTROL STUDY; EPITHELIUM CELL; FEMALE; GENETICS; INTESTINE MUCOSA; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ADULT; AGED; BIOPSY; CASE-CONTROL STUDIES; CASPASE 1; COHORT STUDIES; DNA-BINDING PROTEINS; EPITHELIAL CELLS; FEMALE; HMGB1 PROTEIN; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PHOSPHOPROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84945278159     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000535     Document Type: Article

References (51)

1. Ponder A, Long MD. A clinical review of recent findings in the epidemiology of inflammatory bowel disease. Clin Epidemiol. 2013;5:237-247.
2. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology. 2009;136:1182-1197.
3. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307-317.
4. Rossi O, van Baarlen P, Wells JM. Host-recognition of pathogens and commensals in the mammalian intestine. Curr Top Microbiol Immunol. 2013;358:291-321.
5. McGuckin MA, Eri R, Simms LA, et al. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis. 2009;15:100-113.
6. Aguilera M, Darby T, Melgar S. The complex role of inflammasomes in the pathogenesis of Inflammatory Bowel Diseases-lessons learned from experimental models. Cytokine Growth Factor Rev. 2014;25:715-730.
7. Bauer C, Duewell P, Lehr HA, et al. Protective and aggravating effects of Nlrp3 inflammasome activation in IBD models: influence of genetic and environmental factors. Dig Dis. 2012;30(suppl 1):82-90.
8. Elinav E, Strowig T, Henao-Mejia J, et al. Regulation of the antimicrobial response by NLR proteins. Immunity. 2011;34:665-679.
9. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13:397-411.
10. Rathinam VAK, Vanaja SK, Fitzgerald KA. Regulation of inflammasome signaling. Nat Immunol. 2012;13:333-342.
11. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124.
12. Villani AC, Lemire M, Fortin G, et al. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet. 2009; 41:71-76.
13. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353:2462-2476.
14. Arijs I, De Hertogh G, Machiels K, et al. Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment. Am J Gastroenterol. 2011;106:748-761.
15. Bengtsson H, Simpson K, Bullard J, et al. aroma. affymetrix: A Generic Framework in R for Analyzing Small to Very Large Affymetrix Data Sets in Bounded Memory. Tech Rep. 745. Department of Statistics, University of California Berkeley: Berkeley, CA, 2008.
16. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.
17. Benjamini Y, Hochberg Y. Controlling the false discovery rate-A practical and powerful approach to multiple testing. J Roy Stat Soc B Met. 1995; 57:289-300.
18. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249-264.
19. Pfaffl MW. A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res. 2001;29:e45.
20. Perrier C, Rutgeerts P. New drug therapies on the horizon for IBD. Dig Dis. 2012;30(suppl 1):100-105.
21. Nakahira K, Haspel JA, Rathinam VA, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol. 2011;12:222-230.
22. Zhou R, Yazdi AS, Menu P, et al. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469:221-225.
23. Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol. 2010;10:210-215.
24. Palomino-Morales RJ, Oliver J, Gomez-Garcia M, et al. Association of ATG16L1 and IRGM genes polymorphisms with inflammatory bowel disease: a meta-Analysis approach. Genes Immun. 2009;10:356-364.
25. Umeno J, Asano K, Matsushita T, et al. Meta-Analysis of published studies identified eight additional common susceptibility loci for Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2011;17:2407-2415.
26. Henckaerts L, Cleynen I, Brinar M, et al. Genetic variation in the autophagy gene ULK1 and risk of Crohn's disease. Inflamm Bowel Dis. 2011;17: 1392-1397.
27. Hoefkens E, Nys K, John JM, et al. Genetic association and functional role of Crohn disease risk alleles involved in microbial sensing, autophagy, and endoplasmic reticulum (ER) stress. Autophagy. 2013;9:2046-2055.
28. Nys K, Agostinis P, Vermeire S. Autophagy: a new target or an old strategy for the treatment of Crohn's disease? Nat Rev Gastroenterol Hepatol. 2013;10:395-401.
29. Strisciuglio C, Duijvestein M, Verhaar AP, et al. Impaired autophagy leads to abnormal dendritic cell-epithelial cell interactions. J Crohns Colitis. 2013;7:534-541.
30. Zeissig S, Bojarski C, Buergel N, et al. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut. 2004;53:1295-1302.
31. Hagiwara C, Tanaka M, Kudo H. Increase in colorectal epithelial apoptotic cells in patients with ulcerative colitis ultimately requiring surgery. J Gastroenterol Hepatol. 2002;17:758-764.
32. Shimada K, Crother TR, Karlin J, et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity. 2012;36:401-414.
33. Kim S, Bauernfeind F, Ablasser A, et al. Listeria monocytogenes is sensed by the NLRP3 and AIM2 inflammasome. Eur J Immunol. 2010;40:1545-1551.
34. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122:44-54.
35. Kaur N, Chen CC, Luther J, et al. Intestinal dysbiosis in inflammatory bowel disease. Gut Microbes. 2011;2:211-216.
36. Tamboli CP, Neut C, Desreumaux P, et al. Dysbiosis in inflammatory bowel disease. Gut. 2004;53:1-4.
37. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science. 2001;292:1115-1118.
38. Jin LQ, Li JW, Wang SQ, et al. Detection and identification of intestinal pathogenic bacteria by hybridization to oligonucleotide microarrays. World J Gastroenterol. 2005;11:7615-7619.
39. Lamkanfi M, Dixit VM. Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol. 2012;28:137-161.
40. Duan X, Ponomareva L, Veeranki S, et al. Differential roles for the interferoninducible IFI16 and AIM2 innate immune sensors for cytosolic DNA in cellular senescence of human fibroblasts. Mol Cancer Res. 2011;9:589-602.
41. Haller O, Kochs G, Weber F. The interferon response circuit: induction and suppression by pathogenic viruses. Virology. 2006;344:119-130.
42. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157:1261-1270.
43. Foxman EF, Iwasaki A. Genome-virome interactions: examining the role of common viral infections in complex disease. Nat Rev Microbiol. 2011; 9:254-264.
44. Cadwell K, Patel KK, Maloney NS, et al. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell. 2010;141:1135-1145.
45. Cadwell K, Liu JY, Brown SL, et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal paneth cells. Nature. 2008;456:259-263.
46. Fernandes-Alnemri T, Yu JW, Juliana C, et al. The AIM2 inflammasome is critical for innate immunity to francisella tularensis. Nat Immunol. 2010;11:385-393.
47. Rathinam VA, Jiang Z, Waggoner SN, et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol. 2010;11:395-402.
48. Vermeire S, Ferrante M, Rutgeerts P. Recent advances: personalised use of current Crohn's disease therapeutic options. Gut. 2013;62:1511-1515.
49. Bauer C, Duewell P, Mayer C, et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut. 2010;59:1192-1199.
50. Zaki MH, Boyd KL, Vogel P, et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity. 2010;32:379-391.
51. Lewis GJ, Massey DC, Zhang H, et al. Genetic association between NLRP3 variants and Crohn's disease does not replicate in a large UK panel. Inflamm Bowel Dis. 2011;17:1387-1391.